Official Title
A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir (PAXLOVID TM) in the Kingdom of Saudi Arabia (KSA).
Brief Summary
The aim of this study is to describe the baseline demographic, clinical characteristics,and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have beenprescribed nirmatrelvir, ritonavir treatment.
Detailed Description
Not Provided
Completed
COVID-19
Drug: nirmatrelvir, ritonavir
single cohort
Other Name: Paxlovid
Eligibility Criteria
Inclusion Criteria:
- Confirmed COVID-19 infection during the study observation period
- Nirmatrelvir, ritonavir written prescription
Exclusion Criteria:
- None
Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Saudi Arabia
Locations
King Faisal Specialist Hospital & research center - Jeddah
Jeddah 105343, Saudi Arabia
King Abdulaziz Medical City
Riyadh 108410, Saudi Arabia
King Faisal Specialist Hospital and Research Center
Riyadh 108410, Saudi Arabia
Pfizer CT.gov Call Center, Study Director
Pfizer
Pfizer
NCT Number
Keywords
Paxlovid
Saudi Arabia
MeSH Terms
COVID-19
Nirmatrelvir and ritonavir drug combination